ID

34154

Beschreibung

Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32; ODM derived from: https://clinicaltrials.gov/show/NCT01286233

Link

https://clinicaltrials.gov/show/NCT01286233

Stichworte

  1. 14.01.19 14.01.19 -
Rechteinhaber

see on clinicaltrials.gov

Hochgeladen am

14. Januar 2019

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0

Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Breast Cancer NCT01286233

Eligibility Breast Cancer NCT01286233

Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
the patient must have consented to participate and must have signed and dated an appropriate irb-approved consent form that conforms to federal and institutional guidelines for the ma.32.f study before being enrolled.
Beschreibung

ID.1

Datentyp

boolean

the patient must be female.
Beschreibung

ID.2

Datentyp

boolean

the patient must reside in the united states or canada.
Beschreibung

ID.3

Datentyp

boolean

the patient must be english-speaking.
Beschreibung

ID.4

Datentyp

boolean

the patient must be eligible for randomization in the ma.32 treatment trial. (participation in the ma.32 qol study is permitted but not required.)
Beschreibung

ID.5

Datentyp

boolean

the patient must not have started taking ma.32 study therapy.
Beschreibung

ID.6

Datentyp

boolean

the patient must have completed primary breast radiation therapy at least two weeks prior to enrollment in ma.32.f.
Beschreibung

ID.7

Datentyp

boolean

Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
ma.32 study therapy has been initiated.
Beschreibung

ID.8

Datentyp

boolean

currently receiving radiation therapy or additional radiation therapy is planned for initiation after starting ma.32 study therapy.
Beschreibung

ID.9

Datentyp

boolean

Ähnliche Modelle

Eligibility Breast Cancer NCT01286233

Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
the patient must have consented to participate and must have signed and dated an appropriate irb-approved consent form that conforms to federal and institutional guidelines for the ma.32.f study before being enrolled.
boolean
ID.2
Item
the patient must be female.
boolean
ID.3
Item
the patient must reside in the united states or canada.
boolean
ID.4
Item
the patient must be english-speaking.
boolean
ID.5
Item
the patient must be eligible for randomization in the ma.32 treatment trial. (participation in the ma.32 qol study is permitted but not required.)
boolean
ID.6
Item
the patient must not have started taking ma.32 study therapy.
boolean
ID.7
Item
the patient must have completed primary breast radiation therapy at least two weeks prior to enrollment in ma.32.f.
boolean
Item Group
C0680251 (UMLS CUI)
ID.8
Item
ma.32 study therapy has been initiated.
boolean
ID.9
Item
currently receiving radiation therapy or additional radiation therapy is planned for initiation after starting ma.32 study therapy.
boolean

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video